A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases
A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases
复制标题
DOI：
10.1007/s10434-001-0741-x
复制
发表时间：
2001-10-01
影响因子：
3.7
通讯作者：
Libutti, SK
中科院分区：
文献类型：
--
作者：
Feldman, AL;Alexander, HR;Libutti, SK
背景资料：循环血管生成抑制剂已被认为影响癌症患者远处微转移性疾病的生长。本研究旨在评估大肠癌肝转移患者的循环内皮抑素水平。方法：采用竞争性酶免疫分析法检测30例大肠癌肝转移患者血浆中内皮抑素和血管内皮生长因子（VEGF）的水平。将样本与来自年龄和性别匹配的健康对照的血浆进行比较;高于对照平均值的值> 2SD被认为是升高的。结果：30名癌症患者的血浆内皮抑素水平显著高于对照组（P < .0001），并且与术前VEGF水平相关（P = .0008）。18例患者接受了手术治疗（肝切除术，n = 10;或美法仑隔离肝灌注，n = 8）。17例接受治疗的患者可接受随访。11例进展患者中有8例在进展时血浆内皮抑制素水平升高。在末次随访时，六名保持无进展的患者中没有一人的内皮抑制素水平升高（P = 0.02）。结论：结直肠癌肝转移患者的血浆内皮抑制素水平升高，并与VEGF水平相关。随访期间内皮抑素水平升高与疾病进展相关。了解内源性内皮抑素在癌症患者中的作用可能会导致抑制肿瘤血管生成的新策略。
Background: Circulating inhibitors of angiogenesis have been suggested to affect the growth of distant micrometastatic disease in patients with cancer. This study was designed to evaluate circulating endostatin levels in colorectal cancer patients with liver metastases.Methods: Plasma samples from 30 colorectal cancer patients with liver metastases were analyzed for endostatin and vascular endothelial growth factor (VEGF) by using competitive enzyme immunoassays. Samples were compared with plasma from age- and sex-matched healthy controls; values >2 SD above the control mean were considered elevated,Results: Plasma endostatin levels were significantly higher in the 30 cancer patients than controls (P < .0001) and correlated with preoperative VEGF levels (P = .0008). Eighteen patients underwent surgical treatment (liver resection, n = 10; or isolated hepatic perfusion with melphalan, n = 8). Seventeen treated patients were available for follow-up. Eight of 11 patients who progressed had elevated plasma endostatin levels at the time of progression. None of six patients who remained progression free had elevated endostatin levels at last follow-up (P = .02).Conclusions: Plasma endostatin levels are elevated in colorectal cancer patients with liver metastases and correlate with VEGF levels. Elevated endostatin levels during follow-up are associated with disease progression. Understanding the role of endogenous endostatin in cancer patients may lead to novel strategies to inhibit tumor angiogenesis.